Raymond James Financial Inc. Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Raymond James Financial Inc. purchased a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 54,783 shares of the company's stock, valued at approximately $761,000. Raymond James Financial Inc. owned about 0.11% of Tyra Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of TYRA. Rhumbline Advisers increased its position in Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after purchasing an additional 1,027 shares during the last quarter. Barclays PLC increased its holdings in Tyra Biosciences by 200.5% in the third quarter. Barclays PLC now owns 37,625 shares of the company's stock worth $884,000 after buying an additional 25,106 shares during the last quarter. JPMorgan Chase & Co. raised its position in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after acquiring an additional 3,896 shares in the last quarter. Alta Partners Management Company L.P. acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $56,716,000. Finally, Victory Capital Management Inc. grew its position in Tyra Biosciences by 88.3% in the fourth quarter. Victory Capital Management Inc. now owns 56,640 shares of the company's stock worth $787,000 after acquiring an additional 26,560 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TYRA has been the topic of several analyst reports. Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Trading Up 0.2 %

NASDAQ:TYRA traded up $0.02 during trading hours on Friday, hitting $10.09. 394,066 shares of the company traded hands, compared to its average volume of 259,260. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60. The firm has a 50-day moving average of $9.64 and a 200 day moving average of $13.31. The stock has a market capitalization of $535.68 million, a price-to-earnings ratio of -6.27 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.